Inflammatory bowel disease is a major cause of suffering in the developed world. Pro-inflammatory cytokines, chemokines and eicosanoids are present in high concentrations in inflammatory bowel disease. Many of these inflammatory mediators can be positively regulated by nuclear factor kappa B (NF-kappaB) family of transcription factors. However, it is not known if NF-kappaB activation in vivo promotes intestinal inflammation, or plays a role in protective host responses by inhibiting apoptosis in the inflamed intestine. Our central hypothesis is that NF-kappaB activation in cells of the innate immune system regulates intestinal inflammation and host responses to inflammation in vivo. This hypothesis will be tested by studying the key molecule that activates NF-kappaB, inhibitory kappa B kinase beta (IKKbeta). Studies in specific aim 1 will generate and characterize a transgenic mouse line that expresses cre recombinase exclusively in intestinal epithelial cells. Studies in specific aim 2 will determine the role of IKKbeta in the activation of NF-kappa B in cells of the mucosal innate immune system. Two conditional knockout mouse strains will be generated by cre/loxP-mediated recombinant of the IKKbeta locus: a) Mice that express cre recombinase in intestinal epithelial cells will be crossed with mice bearing a loxP-flanked IKKbeta locus to produce intestinal epithelial IKKbeta knockout mice; b) Existing mice that express cre recombinase in macrophages and neutrophils will be crossed with mice bearing a loxP-flanked IKKbeta locus to produce macrophage and neutrophil IKKbeta knockout mice. Studies in specific aim 3 will determine the role of NF-kappa B activation in the pathogenesis of intestinal inflammation by analzing the course of colitis induced by feeding dextran sulfatesodium to mice that lack IKKbeta in intestinal epithelial cells or in macrophages and neutrophils. The mentored clinical Scientist Development Award will provide me with essential resources with which to perform this research. I will acquire the theoretical and experimental skills to launch a productive independent investigate career with the assistance of this award and of my institution, the Mayo Foundation for Medical Education and Research.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
I kappa B betaanimal breedingcolitisdisease /disorder modelgastrointestinal epitheliumgenetically modified animalslaboratory mousemacrophagemolecular pathologymucosal immunityneutrophilnuclear factor kappa betarecombinase
National Institute of Diabetes and Digestive and Kidney Diseases
CFDA Code
848
DUNS Number
006471700
UEI
Y2K4F9RPRRG7
Project Start Date
15-February-2002
Project End Date
31-January-2007
Budget Start Date
15-February-2002
Budget End Date
31-January-2003
Project Funding Information for 2002
Total Funding
$119,826
Direct Costs
$110,950
Indirect Costs
$8,876
Year
Funding IC
FY Total Cost by IC
2002
National Institute of Diabetes and Digestive and Kidney Diseases
$119,826
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1K08DK060792-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1K08DK060792-01
Patents
No Patents information available for 1K08DK060792-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1K08DK060792-01
Clinical Studies
No Clinical Studies information available for 1K08DK060792-01
News and More
Related News Releases
No news release information available for 1K08DK060792-01
History
No Historical information available for 1K08DK060792-01
Similar Projects
No Similar Projects information available for 1K08DK060792-01